How the landscape is shaping up in MG

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases

In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M

BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more

Plus: Lilly’s RET inhibitor receives accelerated approval for younger patients

Endpoint innovation and success stories are driving a surge in renal disease drug development

Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura

Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product

Vertex’s analgesic heads for submission; plus the latest from Sarepta in DMD, Lilly in hearing loss, and more

Eight biopharmas brought in a combined $949M in follow-on financing; nearly all had gained value by the end of the month